INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248601, 'Diphenoxylate', 'Tasimelteon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293857/', '', 'Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More', 'Loperamide, Eluxadoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248602, 'Diphenoxylate', 'Tetrabenazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293858/', '', 'Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', 'Eluxadoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248603, 'Diphenoxylate', 'Tizanidine', 'Moderate', 'The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects.  In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation.', 'DDInter', 'Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position.  Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.', 'Synergism', 'Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293859/', '', 'Cyclobenzaprine, Methocarbamol, Chlormezanone', 'Eluxadoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248604, 'Diphenoxylate', 'Tramadol', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293860/', '', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248605, 'Diphenoxylate', 'Trihexyphenidyl', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293861/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248606, 'Diphenoxylate', 'Valbenazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293862/', '', 'Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', 'Eluxadoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248607, 'Diphenoxylate', 'Valerian', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293863/', '', 'Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More', 'Loperamide, Eluxadoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248608, 'Diphenoxylate', 'Vigabatrin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293864/', '', 'Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More', 'Loperamide, Eluxadoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248609, 'Diphenoxylate', 'Ziconotide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293865/', '', 'Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid', 'Loperamide, Eluxadoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248610, 'Diphenoxylate', 'Zonisamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293866/', '', 'Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More', 'Eluxadoline, Difenoxin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248611, 'Abciximab', 'Phenyl salicylate', 'Moderate', 'Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function.  Arterial puncture sites may be most problematic.', 'DDInter', 'It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.  Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites.  Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.', 'Synergism', 'It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293867/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248612, 'Acetohexamide', 'Phenyl salicylate', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293868/', '', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248613, 'Alendronic acid', 'Phenyl salicylate', 'Moderate', 'Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.', 'DDInter', 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.', 'Synergism', 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293869/', '', 'Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248614, 'Aliskiren', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of aliskiren.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.', 'DDInter', 'Patients receiving aliskiren who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', 'Patients receiving aliskiren who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293870/', '', 'Hydrochlorothiazide, Hydrochlorothiazide, Sacubitril, Nebivolol', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248615, 'Alteplase', 'Phenyl salicylate', 'Moderate', 'Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.', 'DDInter', 'Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.  Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.', 'Synergism', 'Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293871/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248616, 'Aluminum hydroxide', 'Phenyl salicylate', 'Moderate', 'Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance', 'DDInter', 'Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.', 'Excretion', 'Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293873/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248617, 'Amikacin', 'Phenyl salicylate', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.', 'DDInter', 'It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.', 'Synergism', 'It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293874/', '', 'Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248618, 'Amikacin (liposome)', 'Phenyl salicylate', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.', 'DDInter', 'It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.', 'Synergism', 'It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293875/', '', 'Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248619, 'Amlodipine', 'Phenyl salicylate', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293876/', '', 'Hydrochlorothiazide, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Pravastatin, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate, Hydrochlorothiazide, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, Ammonium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248620, 'Anisindione', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293877/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248621, 'Anistreplase', 'Phenyl salicylate', 'Moderate', 'Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.', 'DDInter', 'Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.  Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.', 'Synergism', 'Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293878/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248622, 'Phenyl salicylate', 'Apixaban', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293879/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248623, 'Phenyl salicylate', 'Ardeparin', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293880/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248624, 'Phenyl salicylate', 'Argatroban', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293881/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248625, 'Acetylsalicylic acid', 'Phenyl salicylate', 'Moderate', 'Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.', 'DDInter', 'Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.', 'Synergism', 'Concomitant use of more than one salicylate at a time should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293882/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine, More', 'Apomorphine, Fesoterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, Ammonium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248626, 'Azilsartan medoxomil', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.', 'DDInter', 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293883/', '', 'Hydrochlorothiazide, Sacubitril, Nebivolol', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248627, 'Baricitinib', 'Phenyl salicylate', 'Moderate', 'Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.', 'DDInter', 'Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.', 'Synergism', 'Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293884/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248628, 'Benazepril', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.', 'DDInter', 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293885/', '', 'Hydrochlorothiazide, Indapamide, Bisoprolol', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248629, 'Bepridil', 'Phenyl salicylate', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293886/', '', 'Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248630, 'Betamethasone', 'Phenyl salicylate', 'Moderate', 'Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.', 'DDInter', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', 'Metabolism, Excretion', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293887/', '', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248631, 'Betrixaban', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293888/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248632, 'Bismuth subsalicylate', 'Phenyl salicylate', 'Moderate', 'Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.', 'DDInter', 'Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.', 'Synergism', 'Concomitant use of more than one salicylate at a time should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293889/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248633, 'Bivalirudin', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293890/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248634, 'Brinzolamide (ophthalmic)', 'Phenyl salicylate', 'Major', 'The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate toxicity.  The mechanism is unknown but may involve salicylate-induced displacement of CAIs from plasma protein-binding sites and reduced renal clearance, or CAI-induced plasma pH changes resulting in increased amounts of unionised salicylates entering the CNS.', 'DDInter', 'In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended.  If coadministration is necessary, careful monitoring of the patient''s mental status and acid base balance is strongly recommended.  Patients should be advised to promptly notify their physicians if they experience symptoms such as lethargy, tinnitus, confusion, nausea, vomiting, or hyperventilation.', 'Others', 'In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293891/', '', 'Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248635, 'Budesonide', 'Phenyl salicylate', 'Moderate', 'Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.', 'DDInter', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', 'Metabolism, Excretion', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293892/', '', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, More', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248636, 'Bumetanide', 'Phenyl salicylate', 'Minor', 'Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.  The interaction has been demonstrated in patients with ascites secondary to liver cirrhosis and in normal volunteers.  Investigators theorize that salicylates may inhibit the renal effects of loop diuretics that are mediated by prostaglandins, including increases in sodium excretion, renal blood flow, and plasma renin activity.', 'DDInter', 'Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.  No clinical interventions are generally required, but the possibility of a potential interaction should be considered in patients with ascites treated with a loop diuretic and salicylate or salicylate-related product.', 'Antagonism', 'Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293893/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Mitapivat, Methazolamide, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248637, 'Calcium carbonate', 'Phenyl salicylate', 'Moderate', 'Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance', 'DDInter', 'Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.', 'Excretion', 'Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293894/', '', 'Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248638, 'Captopril', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.', 'DDInter', 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293896/', '', 'Hydrochlorothiazide, Indapamide, Bisoprolol', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248639, 'Chlorpropamide', 'Phenyl salicylate', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293897/', '', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248640, 'Choline salicylate', 'Phenyl salicylate', 'Moderate', 'Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.', 'DDInter', 'Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.', 'Synergism', 'Concomitant use of more than one salicylate at a time should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293898/', '', 'Diflunisal, Acetaminophen, Ziconotide, Methoxyflurane', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248641, 'Cinoxacin', 'Phenyl salicylate', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293899/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248642, 'Ciprofloxacin', 'Phenyl salicylate', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293900/', '', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Polymyxin B, More', 'Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248643, 'Citalopram', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293901/', '', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248644, 'Clomipramine', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293902/', '', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Tadalafil, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248645, 'Clopidogrel', 'Phenyl salicylate', 'Moderate', 'Clopidogrel has been shown to potentiate the inhibition of platelet aggregation due to aspirin.', 'DDInter', 'Until further data are available, caution is recommended, especially in patients at risk of bleeding (i.e., GI ulceration), if clopidogrel is coadministered on a long-term basis with drugs that may cause GI lesions.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, red or black stools, or bloody or coffee-ground emesis.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, caution is recommended, especially in patients at risk of bleeding (i.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293903/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Apomorphine, Fesoterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248646, 'Clove', 'Phenyl salicylate', 'Minor', 'Clove and clove oil may potentiate the effects of anticoagulants and other drugs that may affect hemostasis such as platelet inhibitors, thrombolytic agents, and nonsteroidal anti-inflammatory drugs, possibly increasing the risk of bleeding.  Eugenol, the active constituent of clove and clove oil, has been shown to be an inhibitor of platelet activity.', 'DDInter', 'In patients who have used clove and clove oil extensively prior to receiving treatment with anticoagulants or other drugs that may affect hemostasis, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'In patients who have used clove and clove oil extensively prior to receiving treatment with anticoagulants or other drugs that may affect hemostasis, the potential for an interaction should be considered.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293904/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248647, 'Cyclosporine', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present.', 'DDInter', 'Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293906/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248648, 'Dalteparin', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293908/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248649, 'Danaparoid', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293909/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248650, 'Deferasirox', 'Phenyl salicylate', 'Major', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding associated with the use of deferasirox.', 'DDInter', 'Caution is advised if deferasirox is used in combination with NSAIDs.  Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, vomiting blood, anorexia, or black, tarry stools.  Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections.  Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations.  A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy.  Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.  In clinical studies, the daily dosage of deferasirox was reduced by 10 mg/kg for increases of serum creatinine on two consecutive measures (i.e., >33% in patients older than 15 years of age, or >33% and greater than the age-appropriate upper limit of normal in patients younger than 15 years of age).  Care should be taken to maintain adequate hydration in patients who develop diarrhea or vomiting.', 'Synergism', 'Caution is advised if deferasirox is used in combination with NSAIDs.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293910/', '', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248651, 'Deflazacort', 'Phenyl salicylate', 'Moderate', 'Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.', 'DDInter', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', 'Metabolism, Excretion', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293911/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248652, 'Delafloxacin', 'Phenyl salicylate', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293912/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248653, 'Desirudin', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293913/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248654, 'Desvenlafaxine', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293914/', '', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248655, 'Dexamethasone', 'Phenyl salicylate', 'Moderate', 'Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.', 'DDInter', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', 'Metabolism, Excretion', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293915/', '', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Vardenafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248656, 'Dexfenfluramine', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293916/', '', 'Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol', 'Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248657, 'Dexlansoprazole', 'Phenyl salicylate', 'Minor', 'Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates.', 'DDInter', 'In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates. It is only necessary to pay attention to the dosing interval.', 'Absorption', 'In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293917/', '', 'Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248658, 'Dicoumarol', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293918/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248659, 'Didanosine', 'Phenyl salicylate', 'Moderate', 'Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance', 'DDInter', 'Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.', 'Excretion', 'Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293919/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Darifenacin, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248660, 'Digoxin', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase plasma digoxin concentrations and half-life.  The exact mechanism is unknown, but may be related to reduced renal clearance of digoxin.', 'DDInter', 'Patients who require concomitant therapy should be monitored for altered pharmacologic effects of digoxin and for increased plasma levels. The digoxin dosage may require adjustment.  Patients should be advised to notify their physician if they experience nausea, anorexia, visual changes, slow pulse, or irregular heartbeats.', 'Excretion', 'Patients who require concomitant therapy should be monitored for altered pharmacologic effects of digoxin and for increased plasma levels.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293920/', '', 'Digitoxin', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248661, 'Diltiazem', 'Phenyl salicylate', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293922/', '', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate, Nitroglycerin', 'Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248662, 'Dimethyl fumarate', 'Phenyl salicylate', 'Moderate', 'The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.', 'DDInter', 'The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.', 'Synergism', 'The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293923/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248663, 'Diroximel fumarate', 'Phenyl salicylate', 'Moderate', 'The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.', 'DDInter', 'The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.', 'Synergism', 'The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293924/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248664, 'Valproic acid', 'Phenyl salicylate', 'Moderate', 'Salicylates, particularly aspirin, may displace valproate from protein binding sites and inhibit its clearance.', 'DDInter', 'Small single doses of salicylates are unlikely to cause significant effects.  However, patients who take large doses of salicylates or over a prolonged period of time should be closely monitored for clinical and laboratory evidence of valproate toxicity and hepatotoxicity.  Free fraction of valproate may be particularly helpful in detecting this interaction.  Patients should be advised to notify their physician if they experience possible symptoms of toxicity (e.g., malaise, weakness, lethargy, drowsiness, nausea, vomiting, or abdominal pain).', 'Distribution', 'Small single doses of salicylates are unlikely to cause significant effects.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293925/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Darifenacin, Avanafil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248665, 'Donepezil', 'Phenyl salicylate', 'Minor', 'Donepezil may increase gastric acid secretion by increasing cholinergic activity.', 'DDInter', 'Donepezil may increase gastric acid secretion by increasing cholinergic activity.  The risk for gastrointestinal bleeding is, therefore, theoretically increased in patients receiving donepezil in combination with a nonsteroidal anti-inflammatory agent.  Caution is recommended when this combination is used.', 'Synergism', 'Donepezil may increase gastric acid secretion by increasing cholinergic activity.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293926/', '', 'Rivastigmine, Galantamine, Tacrine, Memantine, Ginkgo biloba, Aducanumab', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248666, 'Dorzolamide (ophthalmic)', 'Phenyl salicylate', 'Major', 'The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate toxicity.  The mechanism is unknown but may involve salicylate-induced displacement of CAIs from plasma protein-binding sites and reduced renal clearance, or CAI-induced plasma pH changes resulting in increased amounts of unionised salicylates entering the CNS.', 'DDInter', 'In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended.  If coadministration is necessary, careful monitoring of the patient''s mental status and acid base balance is strongly recommended.  Patients should be advised to promptly notify their physicians if they experience symptoms such as lethargy, tinnitus, confusion, nausea, vomiting, or hyperventilation.', 'Others', 'In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293927/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248667, 'Drospirenone', 'Phenyl salicylate', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim.  Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.  Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.  Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293928/', '', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248668, 'Drotrecogin alfa', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293929/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248669, 'Duloxetine', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293930/', '', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248670, 'Edoxaban', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293931/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248671, 'Enalapril', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.', 'DDInter', 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293932/', '', 'Hydrochlorothiazide, Indapamide, Bisoprolol', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248672, 'Enoxacin', 'Phenyl salicylate', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293933/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248673, 'Enoxaparin', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293934/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248674, 'Eplerenone', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of eplerenone.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.', 'DDInter', 'Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Synergism', 'Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293935/', '', 'Amiloride, Triamterene, Finerenone', 'Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248675, 'Epoprostenol', 'Phenyl salicylate', 'Moderate', 'Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hemorrhagic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293936/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Magnesium hydroxide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248676, 'Eprosartan', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.', 'DDInter', 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293937/', '', 'Hydrochlorothiazide, Sacubitril, Nebivolol', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248677, 'Eptifibatide', 'Phenyl salicylate', 'Moderate', 'Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function.  Arterial puncture sites may be most problematic.', 'DDInter', 'It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.  Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites.  Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.', 'Synergism', 'It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293938/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248678, 'Erlotinib', 'Phenyl salicylate', 'Moderate', 'Coadministration of erlotinib with anti-angiogenic agents, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or taxane-based chemotherapy may increase the risk of gastrointestinal (GI) perforation.', 'DDInter', 'Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.  The manufacturer recommends that erlotinib should be permanently discontinued in patients who develop gastrointestinal perforation.', 'Synergism', 'Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293939/', '', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248679, 'Escitalopram', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293940/', '', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Tadalafil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248680, 'Esomeprazole', 'Phenyl salicylate', 'Minor', 'Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates.', 'DDInter', 'In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates. It is only necessary to pay attention to the dosing interval.', 'Absorption', 'In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293941/', '', 'Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248681, 'Etacrynic acid', 'Phenyl salicylate', 'Minor', 'Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.  The interaction has been demonstrated in patients with ascites secondary to liver cirrhosis and in normal volunteers.  Investigators theorize that salicylates may inhibit the renal effects of loop diuretics that are mediated by prostaglandins, including increases in sodium excretion, renal blood flow, and plasma renin activity.', 'DDInter', 'Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.  No clinical interventions are generally required, but the possibility of a potential interaction should be considered in patients with ascites treated with a loop diuretic and salicylate or salicylate-related product.', 'Antagonism', 'Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293942/', '', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248682, 'Etidronic acid', 'Phenyl salicylate', 'Moderate', 'Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.', 'DDInter', 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.', 'Synergism', 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293943/', '', 'Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248683, 'Felodipine', 'Phenyl salicylate', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293944/', '', 'Propranolol, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Ivabradine, Sotalol, Atenolol, Clevidipine, Mibefradil, Celecoxib, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Magnesium hydroxide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248684, 'Fenfluramine', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293945/', '', 'Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Brivaracetam, Topiramate, Ezogabine, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248685, 'Fludrocortisone', 'Phenyl salicylate', 'Moderate', 'Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.', 'DDInter', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', 'Metabolism, Excretion', 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293947/', '', 'Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248686, 'Fluoxetine', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293948/', '', 'Amitriptyline, Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248687, 'Fluvoxamine', 'Phenyl salicylate', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293949/', '', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Oxybutynin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248688, 'Fondaparinux', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293950/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248689, 'Fosinopril', 'Phenyl salicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.', 'DDInter', 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293951/', '', 'Hydrochlorothiazide, Indapamide, Bisoprolol', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248690, 'Furosemide', 'Phenyl salicylate', 'Minor', 'Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.  The interaction has been demonstrated in patients with ascites secondary to liver cirrhosis and in normal volunteers.  Investigators theorize that salicylates may inhibit the renal effects of loop diuretics that are mediated by prostaglandins, including increases in sodium excretion, renal blood flow, and plasma renin activity.', 'DDInter', 'Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.  No clinical interventions are generally required, but the possibility of a potential interaction should be considered in patients with ascites treated with a loop diuretic and salicylate or salicylate-related product.', 'Antagonism', 'Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293952/', '', 'Bendroflumethiazide, Trichlormethiazide, Chlorthalidone, Metolazone, Hydrochlorothiazide, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248691, 'Gatifloxacin', 'Phenyl salicylate', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293953/', '', 'Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248692, 'Gemifloxacin', 'Phenyl salicylate', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293954/', '', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248693, 'Gentamicin', 'Phenyl salicylate', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.', 'DDInter', 'It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.', 'Synergism', 'It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293955/', '', 'Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248694, 'Glimepiride', 'Phenyl salicylate', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293956/', '', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248695, 'Glipizide', 'Phenyl salicylate', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293957/', '', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248696, 'Glyburide', 'Phenyl salicylate', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', 'DDInter', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293958/', '', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248697, 'Grepafloxacin', 'Phenyl salicylate', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293959/', '', 'Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Oxybutynin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248698, 'Heparin', 'Phenyl salicylate', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.', 'DDInter', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293960/', '', 'Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine, More', 'Apomorphine, Fesoterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, Papaverine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248699, 'Diamorphine', 'Methylene blue', 'Major', 'Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.', 'DDInter', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.', 'Synergism', 'Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293961/', '', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More', 'Acamprosate, Lofexidine, Naltrexone, Varenicline, Nalmefene, Nicotine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (248700, 'Hyaluronidase', 'Phenyl salicylate', 'Minor', 'Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.  These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.', 'DDInter', 'Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.  These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.', 'Antagonism', 'Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/293962/', '', 'Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 1767369485);
